/ Jubilant Receives ANDA Approval For Amlodipine And Olmesartan Medoxomil Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 17 May 2017

Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly-owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Amlodipine and Olmesartan Medoxomil Tablets.

This is the third approval that we have received from the USFDA during the current financial year. As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved, said Jubilant Life Sciences Ltd in its BSE filing on Wednesday, 17 May 2017.

As at 12.35 pm, the stock of Jubilant Life Sciences Ltd was trading down by 0.39% on the BSE.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717